---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-001727"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2025-01-23T23:59:59+00:00"
generated_at: "2026-05-27T14:28:37.210892+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences reports 92.4% PVI success at ~3 months in nsPFA catheter feasibility study

## Summary
- 77 patients treated; first 30 evaluated at ~3 months remap with 92.4% PVI success (109/118 veins).
- 100% acute lesion success with conduction block; total PVI ablation time 11.6±4.5 minutes.
- 1 primary SAE (cardiac perforation) and 2 AEs (vertigo, creatinine elevation) all resolved.
- Company on track to begin IDE study in 2025 for clinical validation.
- Data presented at AF Symposium 2025; live case with 3D mapping on Abbott Ensite X System.

## SEC filing metadata
- accession: 0001437749-25-001727
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2025-01-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774925001727/0001437749-25-001727-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774925001727/plse20250121_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-001727
- JSON: https://secwatch.observer/filing/0001437749-25-001727.json
- Plain text: https://secwatch.observer/filing/0001437749-25-001727.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.